By Dermot Doherty
Qiagen NV (QIA), the Dutch company whose tools are used to predict disease and isolate DNA, may make its second-biggest acquisition to date this year.
Qiagen, based in Venlo, the Netherlands, is in talks with several diagnostics companies and may make a purchase in the “three-digit million dollar” range, Chief Financial Officer Roland Sackers said in a March 8 interview at the company’s research and manufacturing site in Hilden, Germany. He declined to be more specific.
An acquisition of that size would be the company’s second- largest after the 2007 takeover of Digene Corp. of the U.S. for $1.6 billion. Qiagen bought one company in 2010, compared with three the previous year, as valuations of potential targets began to get “very rich,” Sackers said.